調査レポートカテゴリー： MarketsandMarkets, 世界, 医療/バイオ

Stem Cell Therapy Market by Type (Allogeneic, Autologous), Cell Source (Adipose Tissue-derived MSC, Bone Marrow, Placenta/Umbilical Cord), Therapeutic Application (Musculoskeletal, Wounds, Surgeries, Cardiovascular, Neurological) - Global Forecast to 2027

幹細胞療法のグローバル市場予測（～2027）：同種幹細胞療法、自家幹細胞療法

◆タイトル：Stem Cell Therapy Market by Type (Allogeneic, Autologous), Cell Source (Adipose Tissue-derived MSC, Bone Marrow, Placenta/Umbilical Cord), Therapeutic Application (Musculoskeletal, Wounds, Surgeries, Cardiovascular, Neurological) - Global Forecast to 2027
◆商品コード：BT5049-22
◆調査・発行会社：MarketsandMarkets
◆発行日：2022年9月17日
◆ページ数：160
◆レポート形式：PDF / 英語
◆納品方法：Eメール（受注後24時間以内）
◆調査対象地域：グローバル
◆産業分野：医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧）USD4,950 ⇒換算￥0見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算￥0見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算￥0見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※商品の納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。（振込先：三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。（但し、対応範囲は弊社で判断）
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarketsの日本における正規販売代理店です。

 【レポートの概要】

MarketsandMarkets社の最新調査レポートによると、世界の幹細胞療法市場規模は、2022年257百万ドルから2027年558百万ドルまで年平均16.8％成長すると推定されます。当書は、幹細胞療法の世界市場を調査対象とし、イントロダクション、調査手法、エグゼクティブサマリー、プレミアムインサイト、市場概要、種類別（同種幹細胞療法、自家幹細胞療法）分析、細胞源別（脂肪組織由来MSC、骨髄、胎盤/臍帯、その他）分析、治療用途別（筋骨格、創傷、手術、心血管、神経）分析、地域別（北米、ヨーロッパ、アジア太平洋、その他地域）分析、競争状況、企業情報などについて総合的にまとめています。なお、当書に掲載されている企業情報には、Smith+Nephew (UK)、MEDIPOST Co. Ltd. (South Korea) 、Anterogen Co. Ltd. (South Korea)、CORESTEM (South Korea) 、Pharmicell Co. Ltd. (South Korea)、NuVasive Inc. (US)、RTI Surgical (US)、AlloSource (US)、JCR Pharmaceuticals Co. Ltd. (Japan)、Takeda Pharmaceutical Company Limited (Japan) などが含まれています。
・イントロダクション
・調査手法
・エグゼクティブサマリー
・プレミアムインサイト
・市場概要
・世界の幹細胞療法市場規模：種類別
- 同種幹細胞療法の市場規模
- 自家幹細胞療法の市場規模
・世界の幹細胞療法市場規模：細胞源別
- 脂肪組織由来MSCによる幹細胞療法の市場規模
- 骨髄由来MSCによる幹細胞療法の市場規模
- 胎盤/臍帯由来MSCによる幹細胞療法の市場規模
- その他細胞源による幹細胞療法の市場規模
・世界の幹細胞療法市場規模：治療用途別
- 筋骨格用幹細胞療法の市場規模
- 創傷用幹細胞療法の市場規模
- 手術用幹細胞療法の市場規模
- 心血管用幹細胞療法の市場規模
- 神経用幹細胞療法の市場規模
・世界の幹細胞療法市場規模：地域別
- 北米の幹細胞療法市場規模
- ヨーロッパの幹細胞療法市場規模
- アジア太平洋の幹細胞療法市場規模
- その他地域の幹細胞療法市場規模
・競争状況
・企業情報

“The global stem cell therapy market is projected to reach USD 558 million by 2027 from USD 257 million in 2022, at a CAGR of 16.8% during the forecast period.”
Several companies are focusing on developing regenerative medicine due to the rising number of clinical trials conducted on stem cell therapies. The increasing number of clinical trials has largely taken place owing to the rising government and public & private investments for R&D in cell-based therapies, supportive regulatory framework, and accelerated approval provisions by the FDA in regenerative medicine R&D.

“The allogeneic stem cell therapy segment accounted for the highest growth rate in the stem cell therapy market, by type, during the forecast period”
The stem cell therapy market is segmented into allogeneic and autologous stem cell therapy. Allogeneic stem therapy segment accounted for the largest share of the stem cell therapy market. Stem cells used for allogeneic stem cell therapy are obtained from sources other than the target patient, which is usually from a donor. In allogeneic stem cell therapy, one cell source can produce many doses, thus making allogeneic therapy economically viable and less time-consuming. Moreover, it is easier to scale up production processes for allogeneic therapy than for autologous therapy. Currently, more than ten approved commercialized allogeneic stem cell therapies are available globally.

“Bone Marrow-derived MSCs segment accounted for the highest CAGR”
Based on the cell source the global stem cell therapy market is segmented into adipose tissue-derived MSCs (mesenchymal stem cells), bone marrow-derived MSCs, placenta/umbilical cord-derived MSCs, and other cell sources. Bone marrow-derived mesenchymal stem cells are the most preferred type for stem cell therapies. Bone marrow MSCs are readily available, require less in vitro processing, and can be used for autologous and allogeneic stem cell therapy. Over the last decade, the stem cell therapy market has witnessed high demand for several bone marrow-derived stem cell-based products for various therapeutic applications, including immune-deficiency syndromes, hemoglobinopathies, and metabolic disorders. This has collectively contributed the segment’s growth.
 
“Asia Pacific: The fastest-growing country in the stem cell therapy market”
The stem cell therapy market is segmented into North America, Europe, Asia Pacific, RoW. The stem cell therapy market in the Asia Pacific region is expected to grow at the highest CAGR during the forecast period. Rising cases of neurodegenerative disorders drive market growth for stem cell therapy products in India along with favorable government support for stem cell therapy products in South Korea have propelled the growth of Asia Pacific stem cell therapy market.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side- 80% and Demand Side 20%
• By Designation: C-level – 25%, D-level – 20%, and Others – 55%
• By Region: North America -50%, Europe -20%, Asia-Pacific -20%, RoW -10%

Lists of Companies Profiled in the Report:
• Smith+Nephew (UK)
• MEDIPOST Co. Ltd. (South Korea)
• Anterogen Co. Ltd. (South Korea)
• CORESTEM (South Korea)
• Pharmicell Co. Ltd. (South Korea)
• NuVasive Inc. (US)
• RTI Surgical (US)
• AlloSource (US)
• JCR Pharmaceuticals Co. Ltd. (Japan)
• Takeda Pharmaceutical Company Limited (Japan)
• Holostem Terapie Avanzate Srl (Italy)
• Orthofix (US)
• Regrow Biosciences Pvt Ltd. (India)
• STEMPEUTICS RESEARCH PVT LTD. (India)
• Athersys (US)
• Mesoblast Ltd (Australia)
• Biorestorative Therapies Inc. (US)
• Pluristem Inc. (Israel)
• Brainstorm Cell Limited. (US)
• ViaCyte Inc. (US)
• Gamida Cell (US)
• Kangstem Biotech (South Korea)
• Hope Biosciences (US)
• Cellular Biomedicine Group (US)
• Personalized Stem Cells (US)

Research Coverage:
This report provides a detailed picture of the stem cell therapy market. It aims at estimating the size and future growth potential of the market across different segments, such as the type, therapeutic applications, and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall stem cell therapy market and its segments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, trends, opportunities, and challenges.

【レポートの目次】

1 INTRODUCTION 26
1.1 STUDY OBJECTIVES 26
1.2 MARKET DEFINITION 26
1.2.1 INCLUSIONS & EXCLUSIONS 26
1.3 STUDY SCOPE 27
FIGURE 1 STEM CELL THERAPY MARKET 27
1.3.1 YEARS CONSIDERED 27
1.4 CURRENCY CONSIDERED 28
1.5 LIMITATIONS 28
1.6 STAKEHOLDERS 28
1.7 SUMMARY OF CHANGES 29
2 RESEARCH METHODOLOGY 30
2.1 RESEARCH APPROACH 30
FIGURE 2 RESEARCH DESIGN 30
2.1.1 SECONDARY DATA 31
2.1.2 PRIMARY DATA 32
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: STEM CELL THERAPY MARKET 32
2.2 MARKET SIZE ESTIMATION 33
FIGURE 4 MARKET SIZE ESTIMATION: BOTTOM-UP (SUPPLY SIDE): COLLECTIVE REVENUE OF STEM CELL THERAPY MARKET PLAYERS 33
FIGURE 5 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS, 2021 34
FIGURE 6 AVERAGE MARKET SIZE ESTIMATION, 2021 34
2.3 GROWTH FORECAST 36
FIGURE 7 STEM CELL THERAPY MARKET: CAGR PROJECTIONS (2022–2027) 36
FIGURE 8 STEM CELL THERAPY MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, CHALLENGES, AND OPPORTUNITIES 37
FIGURE 9 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 37
2.4 DATA TRIANGULATION 39
FIGURE 10 DATA TRIANGULATION METHODOLOGY 39
2.5 PRIMARY INSIGHTS 40
FIGURE 11 MARKET VALIDATION FROM PRIMARY EXPERTS 40
2.6 RESEARCH ASSUMPTIONS 40
2.7 RISK ASSESSMENT 41
 
3 EXECUTIVE SUMMARY 42
FIGURE 12 STEM CELL THERAPY MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION) 42
FIGURE 13 STEM CELL THERAPY MARKET, BY CELL SOURCE,
2022 VS. 2027 (USD MILLION) 43
FIGURE 14 STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION,
2022 VS. 2026 (USD MILLION) 43
FIGURE 15 GEOGRAPHICAL SNAPSHOT OF STEM CELL THERAPY MARKET 44
4 PREMIUM INSIGHTS 46
4.1 STEM CELL THERAPY MARKET OVERVIEW 46
FIGURE 16 INCREASING INVESTMENTS & FUNDING INITIATIVES FOR STEM CELL RESEARCH TO DRIVE MARKET GROWTH 46
4.2 NORTH AMERICA: STEM CELL THERAPY MARKET 47
FIGURE 17 ALLOGENEIC STEM CELL THERAPY TO COMMAND LARGEST SHARE IN 2021 47
4.3 NORTH AMERICA: STEM CELL THERAPY MARKET, BY CELL SOURCE,
2022 VS. 2027 (USD MILLION) 47
FIGURE 18 BONE MARROW-DERIVED MSCS TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD 47
5 MARKET OVERVIEW 48
5.1 INTRODUCTION 48
FIGURE 19 MARKET DYNAMICS: DRIVERS, OPPORTUNITIES, RESTRAINTS, AND CHALLENGES 48
5.2 MARKET DYNAMICS 49
5.2.1 DRIVERS 49
5.2.1.1 Availability of funding for stem cell research 49
TABLE 1 ICMR FUNDING FOR STEM CELL RESEARCH, 2019–2021 (USD) 49
FIGURE 20 STEM CELL RESEARCH FUNDING IN LAST 10 YEARS 49
TABLE 2 NIH FUNDING FOR CELL-BASED RESEARCH, 2016–2021 (USD MILLION) 50
5.2.1.2 Increasing GMP certification approvals for cell therapy production facilities 50
TABLE 3 NEW GMP FACILITIES, 2017-2020 51
5.2.1.3 Increasing clinical trials for stem cell-based therapies 51
FIGURE 21 NUMBER OF CLINICAL TRIALS (2015-2020) 51
FIGURE 22 CLINICAL TRIALS, BY PHASE 52
5.2.2 RESTRAINTS 52
5.2.2.1 Ethical concerns related to embryonic stem cells 52
5.2.2.2 High cost of cell-based research 52
5.2.3 OPPORTUNITIES 53
5.2.3.1 Emergence of iPSCs as an alternative to ESCs 53
5.2.3.2 Growing demand for cell & gene therapies 53
5.2.4 CHALLENGES 53
5.2.4.1 Technical limitations associated with manufacturing processes 53
 
5.3 TECHNOLOGY ANALYSIS 54
TABLE 4 STEM CELL THERAPIES AND GENE THERAPIES 54
5.4 VALUE CHAIN ANALYSIS 54
FIGURE 23 VALUE CHAIN ANALYSIS OF STEM CELL THERAPY MARKET 55
5.5 ROLE IN ECOSYSTEM 56
FIGURE 24 ECOSYSTEM MARKET MAP 56
5.6 SUPPLY CHAIN ANALYSIS 56
FIGURE 25 SUPPLY CHAIN ANALYSIS OF STEM CELL THERAPY MARKET 57
TABLE 5 SUPPLY CHAIN ANALYSIS: COMMERCIAL SCALE/KEY MANUFACTURERS 57
TABLE 6 SUPPLY CHAIN ANALYSIS: PIPELINE/EMERGING MANUFACTURERS 58
5.7 PORTER’S FIVE FORCES ANALYSIS 58
5.7.1 THREAT OF NEW ENTRANTS 59
5.7.2 THREAT OF SUBSTITUTES 59
5.7.3 BARGAINING POWER OF SUPPLIERS 59
5.7.4 BARGAINING POWER OF BUYERS 59
5.7.5 INTENSITY OF COMPETITION RIVALRY 60
5.8 REGULATORY LANDSCAPE 60
5.8.1 NORTH AMERICA 60
TABLE 7 NORTH AMERICA: REGULATORY LANDSCAPE FOR STEM CELL THERAPIES 60
5.8.2 EUROPE 62
TABLE 8 EUROPE: REGULATORY LANDSCAPE FOR STEM CELL THERAPIES 62
5.8.3 ASIA PACIFIC 63
TABLE 9 ASIA PACIFIC: REGULATORY LANDSCAPE FOR STEM CELL THERAPIES 63
5.8.4 REST OF THE WORLD 65
TABLE 10 ROW: REGULATORY LANDSCAPE FOR STEM CELL THERAPIES 65
5.9 PRICING ANALYSIS 66
5.9.1 PRICING ANALYSIS 66
TABLE 11 AVERAGE SELLING PRICES OF KEY PLAYERS 66
5.9.2 AVERAGE SELLING PRICE TREND – STEM CELL THERAPY TREATMENT 66
5.10 PATENT ANALYSIS 67
FIGURE 26 PATENT ANALYSIS OF STEM CELL THERAPIES IN LAST 10 YEARS (2011-2020) 67
5.11 KEY CONFERENCES & EVENTS IN 2022–2023 67
5.11.1 STEM CELL THERAPY CONFERENCES (2022–2023) 67
TABLE 12 STEM CELL THERAPY CONFERENCES (2022–2023) 67
5.12 DISRUPTIONS & TRENDS IMPACTING CUSTOMERS’ BUSINESSES 68
5.13 KEY STAKEHOLDERS AND BUYING CRITERIA 68
FIGURE 27 KEY STAKEHOLDERS IN STEM CELL THERAPY MARKET 68
FIGURE 28 KEY BUYING CRITERIA FOR END USERS 69
FIGURE 29 REVENUE SHIFT & NEW POCKET FOR STEM CELL THERAPY COMPANIES 69
 
6 STEM CELL THERAPY MARKET, BY TYPE 70
6.1 INTRODUCTION 71
TABLE 13 STEM CELL THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 71
6.2 ALLOGENEIC STEM CELL THERAPY 71
6.2.1 FAVORABLE SCALING UP OF PRODUCTION PROCESSES TO DRIVE SEGMENT 71
TABLE 14 ALLOGENEIC STEM CELL THERAPY MARKET, BY REGION,
2020–2027 (USD MILLION) 71
TABLE 15 NORTH AMERICA: ALLOGENEIC STEM CELL THERAPY MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 72
TABLE 16 EUROPE: ALLOGENEIC STEM CELL THERAPY MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 72
TABLE 17 ASIA PACIFIC: ALLOGENEIC STEM CELL THERAPY MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 72
6.3 AUTOLOGOUS STEM CELL THERAPY 73
6.3.1 LOW RISK OF POST-TREATMENT COMPLICATIONS TO DRIVE SEGMENT 73
TABLE 18 AUTOLOGOUS STEM CELL THERAPY MARKET, BY REGION,
2020–2027 (USD MILLION) 73
TABLE 19 NORTH AMERICA: AUTOLOGOUS STEM CELL THERAPY MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 73
TABLE 20 EUROPE: AUTOLOGOUS STEM CELL THERAPY MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 74
TABLE 21 ASIA PACIFIC: AUTOLOGOUS STEM CELL THERAPY MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 74
7 STEM CELL THERAPY MARKET, BY CELL SOURCE 75
7.1 INTRODUCTION 76
TABLE 22 STEM CELL THERAPY MARKET, BY CELL SOURCE, 2020–2027 (USD MILLION) 76
7.2 ADIPOSE TISSUE-DERIVED MSCS 76
7.2.1 PROPERTIES SUCH AS SIMPLIFIED HARVESTING & EASE OF ISOLATION TO DRIVE MARKET 76
TABLE 23 STEM CELL THERAPY MARKET FOR ADIPOSE TISSUE-DERIVED MSCS, BY REGION, 2020–2027 (USD MILLION) 77
TABLE 24 NORTH AMERICA: STEM CELL THERAPY MARKET FOR ADIPOSE TISSUE-DERIVED MSCS, BY COUNTRY, 2020–2027 (USD MILLION) 77
TABLE 25 EUROPE: STEM CELL THERAPY MARKET FOR ADIPOSE-TISSUE DERIVED MSCS, BY COUNTRY, 2020–2027 (USD MILLION) 77
TABLE 26 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR ADIPOSE-TISSUE DERIVED MSCS, BY COUNTRY, 2020–2027 (USD MILLION) 78
7.3 BONE MARROW-DERIVED MSCS 78
7.3.1 HIGH PREVALENCE OF METABOLIC DISORDERS TO DRIVE MARKET 78
TABLE 27 STEM CELL THERAPY MARKET FOR BONE MARROW-DERIVED MSCS, BY REGION, 2020–2027 (USD MILLION) 79
TABLE 28 NORTH AMERICA: STEM CELL THERAPY MARKET FOR BONE MARROW-DERIVED MSCS, BY COUNTRY, 2020–2027 (USD MILLION) 79
TABLE 29 EUROPE: STEM CELL THERAPY MARKET FOR BONE MARROW-DERIVED MSCS, BY COUNTRY, 2020–2027 (USD MILLION) 79
TABLE 30 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR BONE MARROW-DERIVED MSCS, BY COUNTRY, 2020–2027 (USD MILLION) 80
7.4 PLACENTA/UMBILICAL CORD-DERIVED MSCS 80
7.4.1 LOWER CHANCES OF IMMUNE REJECTION TO SUPPORT MARKET 80
TABLE 31 STEM CELL THERAPY MARKET FOR PLACENTA/UMBILICAL CORD-DERIVED MSCS, BY REGION, 2020–2027 (USD MILLION) 80
TABLE 32 NORTH AMERICA: STEM CELL THERAPY MARKET FOR PLACENTA/UMBILICAL CORD-DERIVED MSCS, BY COUNTRY, 2020–2027 (USD MILLION) 81
TABLE 33 EUROPE: STEM CELL THERAPY MARKET FOR PLACENTA/UMBILICAL CORD-DERIVED MSCS, BY COUNTRY, 2020–2027 (USD MILLION) 81
TABLE 34 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR PLACENTA/UMBILICAL CORD-DERIVED MSCS, BY COUNTRY, 2020–2027 (USD MILLION) 81
7.5 OTHER CELL SOURCES 82
TABLE 35 STEM CELL THERAPY MARKET FOR OTHER CELL SOURCES, BY REGION, 2020–2027 (USD MILLION) 82
TABLE 36 NORTH AMERICA: STEM CELL THERAPY MARKET FOR OTHER CELL SOURCES, BY COUNTRY, 2020–2027 (USD MILLION) 82
TABLE 37 EUROPE: STEM CELL THERAPY MARKET FOR OTHER CELL SOURCES,
BY COUNTRY, 2020–2027 (USD MILLION) 83
TABLE 38 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR OTHER CELL SOURCES,
BY COUNTRY, 2020–2027 (USD MILLION) 83
8 STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION 84
8.1 INTRODUCTION 85
TABLE 39 STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION) 85
8.2 MUSCULOSKELETAL DISORDERS 85
8.2.1 RISING INCIDENCE OF OSTEOARTHRITIS TO DRIVE MARKET 85
TABLE 40 STEM CELL THERAPY MARKET FOR MUSCULOSKELETAL DISORDERS,
BY REGION, 2020–2027 (USD MILLION) 86
TABLE 41 NORTH AMERICA: STEM CELL THERAPY MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION) 86
TABLE 42 EUROPE: STEM CELL THERAPY MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION) 86
TABLE 43 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION) 87
8.3 WOUNDS & INJURIES 87
8.3.1 GROWING BENEFITS OF ALLOGENEIC-BASED THERAPIES TO SUPPORT MARKET GROWTH 87
TABLE 44 STEM CELL THERAPY MARKET FOR WOUNDS & INJURIES,
BY REGION, 2020–2027 (USD MILLION) 87
TABLE 45 NORTH AMERICA: STEM CELL THERAPY MARKET FOR WOUNDS & INJURIES, BY COUNTRY, 2020–2027 (USD MILLION) 88
TABLE 46 EUROPE: STEM CELL THERAPY MARKET FOR WOUNDS & INJURIES,
BY COUNTRY, 2020–2027 (USD MILLION) 88
TABLE 47 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR WOUNDS & INJURIES,
BY COUNTRY, 2020–2027 (USD MILLION) 88
 
8.4 INFLAMMATORY & AUTOIMMUNE DISEASES 89
8.4.1 INCREASING CLINICAL TRIALS FOR BONE MARROW-DERIVED MSCS TO SUPPORT MARKET GROWTH 89
TABLE 48 STEM CELL THERAPY MARKET FOR INFLAMMATORY & AUTOIMMUNE DISEASES, BY REGION, 2020–2027 (USD MILLION) 89
TABLE 49 NORTH AMERICA: STEM CELL THERAPY MARKET FOR INFLAMMATORY & AUTOIMMUNE DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 89
TABLE 50 EUROPE: STEM CELL THERAPY MARKET FOR INFLAMMATORY & AUTOIMMUNE DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 90
TABLE 51 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR INFLAMMATORY & INFLAMMATORY DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 90
8.5 SURGERIES 91
8.5.1 GROWING CLINICAL RESEARCH FOR SURGICAL APPLICATIONS TO SUPPORT MARKET GROWTH 91
TABLE 52 STEM CELL THERAPY MARKET FOR SURGERIES, BY REGION,
2020–2027 (USD MILLION) 91
TABLE 53 NORTH AMERICA: STEM CELL THERAPY MARKET FOR SURGERIES,
BY COUNTRY, 2020–2027 (USD MILLION) 91
TABLE 54 EUROPE: STEM CELL THERAPY MARKET FOR SURGERIES, BY COUNTRY, 2020–2027 (USD MILLION) 92
TABLE 55 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR SURGERIES, BY COUNTRY, 2020–2027 (USD MILLION) 92
8.6 CARDIOVASCULAR DISEASES 92
8.6.1 RISING DEMAND FOR CVD TREATMENTS TO SUPPORT MARKET GROWTH 92
TABLE 56 STEM CELL THERAPY MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2020–2027 (USD MILLION) 93
TABLE 57 NORTH AMERICA: STEM CELL THERAPY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 93
TABLE 58 EUROPE: STEM CELL THERAPY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 93
TABLE 59 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 94
8.7 NEUROLOGICAL DISORDERS 94
8.7.1 RISING PREVALENCE OF NEUROGENERATIVE DISORDERS TO SUPPORT MARKET GROWTH 94
TABLE 60 STEM CELL THERAPY MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2020–2027 (USD MILLION) 94
TABLE 61 NORTH AMERICA: STEM CELL THERAPY MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION) 95
TABLE 62 EUROPE: STEM CELL THERAPY MARKET FOR NEUROLOGICAL DISORDERS,
BY COUNTRY, 2020–2027 (USD MILLION) 95
TABLE 63 ASIA PACIFIC: STEM CELL THERAPY MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION) 95
8.8 OTHER THERAPEUTIC APPLICATIONS 96
TABLE 64 STEM CELL THERAPY FOR OTHER THERAPEUTIC APPLICATIONS, BY REGION, 2020–2027 (USD MILLION) 96
TABLE 65 NORTH AMERICA: STEM CELL THERAPY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 96
TABLE 66 EUROPE: STEM CELL THERAPY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 97
TABLE 67 ASIA PACIFIC: STEM CELL THERAPY FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 97
9 STEM CELL THERAPY MARKET, BY REGION 98
9.1 INTRODUCTION 99
TABLE 68 STEM CELL THERAPY MARKET, BY REGION, 2020–2027 (USD MILLION) 99
9.2 NORTH AMERICA 99
FIGURE 30 NORTH AMERICA: STEM CELL THERAPY MARKET SNAPSHOT 100
TABLE 69 NORTH AMERICA: STEM CELL THERAPY MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 100
TABLE 70 NORTH AMERICA: STEM CELL THERAPY MARKET, BY CELL SOURCE,
2020–2027 (USD MILLION) 101
TABLE 71 NORTH AMERICA: STEM CELL THERAPY MARKET, BY TYPE,
2020–2027 (USD MILLION) 101
TABLE 72 NORTH AMERICA: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION) 101
9.2.1 US 102
9.2.1.1 Rising approvals for stem cell therapy products to drive market 102
FIGURE 31 NIH FUNDING IN LAST 10 YEARS (2011–2021) 102
TABLE 73 US: STEM CELL THERAPY MARKET, BY CELL SOURCE,
2020–2027 (USD MILLION) 102
TABLE 74 US: STEM CELL THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 103
TABLE 75 US: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION,
2020–2027 (USD MILLION) 103
9.2.2 CANADA 103
9.2.2.1 Increasing government focus on targeted stem cell therapy treatment to drive market 103
TABLE 76 CANADA: STEM CELL THERAPY MARKET, BY CELL SOURCE,
2020–2027 (USD MILLION) 104
TABLE 77 CANADA: STEM CELL THERAPY MARKET, BY TYPE,
2020–2027 (USD MILLION) 104
TABLE 78 CANADA: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION) 105
9.3 EUROPE 105
TABLE 79 EUROPE: STEM CELL THERAPY MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 105
TABLE 80 EUROPE: STEM CELL THERAPY MARKET, BY CELL SOURCE,
2020–2027 (USD MILLION) 106
TABLE 81 EUROPE: STEM CELL THERAPY MARKET, BY TYPE,
2020–2027 (USD MILLION) 106
TABLE 82 EUROPE: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION) 106
9.3.1 GERMANY 107
9.3.1.1 Strong R&D base and growing focus on minimally invasive treatments to drive market 107
TABLE 83 GERMANY: STEM CELL THERAPY MARKET, BY CELL SOURCE,
2020–2027 (USD MILLION) 107
TABLE 84 GERMANY: STEM CELL THERAPY MARKET, BY TYPE,
2020–2027 (USD MILLION) 107
TABLE 85 GERMANY: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION) 108
9.3.2 UK 108
9.3.2.1 Rising adoption of cell-based therapies to drive market 108
TABLE 86 UK: STEM CELL THERAPY MARKET, BY CELL SOURCE,
2020–2027 (USD MILLION) 109
TABLE 87 UK: STEM CELL THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 109
TABLE 88 UK: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION,
2020–2027 (USD MILLION) 109
9.3.3 FRANCE 110
9.3.3.1 Rising healthcare expenditure to support uptake of stem cell therapy products 110
TABLE 89 FRANCE: STEM CELL THERAPY MARKET, BY CELL SOURCE,
2020–2027 (USD MILLION) 110
TABLE 90 FRANCE: STEM CELL THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 110
TABLE 91 FRANCE: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION) 111
9.3.4 REST OF EUROPE 111
TABLE 92 REST OF EUROPE: STEM CELL THERAPY MARKET, BY CELL SOURCE,
2020–2027 (USD MILLION) 111
TABLE 93 REST OF EUROPE: STEM CELL THERAPY MARKET, BY TYPE,
2020–2027 (USD MILLION) 112
TABLE 94 REST OF EUROPE: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION) 112
9.4 ASIA PACIFIC 113
FIGURE 32 ASIA PACIFIC: STEM CELL THERAPY MARKET SNAPSHOT 113
TABLE 95 ASIA PACIFIC: STEM CELL THERAPY MARKET, BY CELL SOURCE,
2020–2027 (USD MILLION) 114
TABLE 96 ASIA PACIFIC: STEM CELL THERAPY MARKET, BY TYPE,
2020–2027 (USD MILLION) 114
TABLE 97 ASIA PACIFIC: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION) 114
9.4.1 JAPAN 115
9.4.1.1 Growing geriatric population and rapid regulatory processes to drive market 115
TABLE 98 JAPAN: STEM CELL THERAPY MARKET, BY CELL SOURCE,
2020–2027 (USD MILLION) 115
TABLE 99 JAPAN: STEM CELL THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 115
TABLE 100 JAPAN: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION) 116
9.4.2 SOUTH KOREA 116
9.4.2.1 Favorable government support for stem cell therapy products to support market growth 116
TABLE 101 SOUTH KOREA: STEM CELL THERAPY MARKET, BY CELL SOURCE,
2020–2027 (USD MILLION) 116
TABLE 102 SOUTH KOREA: STEM CELL THERAPY MARKET, BY TYPE,
2020–2027 (USD MILLION) 117
TABLE 103 SOUTH KOREA: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION) 117
9.4.3 INDIA 117
9.4.3.1 Rising cases of neurodegenerative disorders drive market 117
TABLE 104 INDIA: STEM CELL THERAPY MARKET, BY CELL SOURCE,
2020–2027 (USD MILLION) 118
TABLE 105 INDIA: STEM CELL THERAPY MARKET, BY TYPE, 2020–2027 (USD MILLION) 118
TABLE 106 INDIA: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION,
2020–2027 (USD MILLION) 118
9.4.4 REST OF ASIA PACIFIC 119
TABLE 107 REST OF ASIA PACIFIC: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2020–2027 (USD MILLION) 119
TABLE 108 REST OF ASIA PACIFIC: STEM CELL THERAPY MARKET, BY TYPE,
2020–2027 (USD MILLION) 119
TABLE 109 REST OF ASIA PACIFIC: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION) 120
9.5 REST OF THE WORLD 120
TABLE 110 REST OF THE WORLD: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2020–2027 (USD MILLION) 121
TABLE 111 REST OF THE WORLD: STEM CELL THERAPY MARKET, BY TYPE,
2020–2027 (USD MILLION) 121
TABLE 112 REST OF THE WORLD: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2020–2027 (USD MILLION) 121
10 COMPETITIVE LANDSCAPE 122
10.1 INTRODUCTION 122
10.2 STRATEGIES ADOPTED BY KEY PLAYERS/RIGHT TO WIN 122
FIGURE 33 STEM CELL THERAPY MARKET: STRATEGIES ADOPTED 123
10.3 REVENUE SHARE ANALYSIS 123
10.4 MARKET SHARE ANALYSIS (2021) 124
10.5 COMPANY EVALUATION QUADRANT (KEY MARKET PLAYERS) 125
10.5.1 STARS 126
10.5.2 EMERGING LEADERS 126
10.5.3 PERVASIVE PLAYERS 126
10.5.4 PARTICIPANTS 126
FIGURE 36 STEM CELL THERAPY MARKET: COMPANY EVALUATION QUADRANT FOR APPROVED PRODUCTS (2021) 127
10.6 COMPETITIVE BENCHMARKING 128
10.6.1 STEM CELL THERAPY MARKET: A DETAILED LIST OF STARTUPS/SMES 128
TABLE 113 STEM CELL THERAPY MARKET: DETAILED LIST OF STARTUPS/SMES 128
10.6.2 STEM CELL THERAPY MARKET: COMPETITIVE BENCHMARKING OF OTHER PLAYERS [STARTUPS/SMES) 129
TABLE 114 STEM CELL THERAPY MARKET: COMPETITIVE BENCHMARKING OF OTHER PLAYERS [STARTUPS/SMES] 129
10.7 COMPANY EVALUATION QUADRANT (SMES/START-UPS) 130
10.7.1 PROGRESSIVE COMPANIES 130
10.7.2 STARTING BLOCKS 130
10.7.3 RESPONSIVE COMPANIES 130
10.7.4 DYNAMIC COMPANIES 130
FIGURE 37 STEM CELL THERAPY MARKET: COMPANY EVALUATION QUADRANT FOR PRODUCTS UNDER PIPELINE (2021) 131
10.8 COMPANY PRODUCT FOOTPRINT ANALYSIS 132
TABLE 115 COMPANY PRODUCT FOOTPRINT 132
10.9 COMPANY FOOTPRINT OF MAJOR PLAYERS 133
TABLE 116 COMPANY REGIONAL FOOTPRINT 133
10.10 COMPETITIVE SCENARIO 134
TABLE 117 STEM CELL THERAPY MARKET: REGULATORY APPROVALS 134
TABLE 118 STEM CELL THERAPY MARKET: DEALS 134
11 COMPANY PROFILES 135
11.1 MAJOR PLAYERS 135
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
11.1.1 SMITH+NEPHEW 135
TABLE 119 SMITH+NEPHEW: BUSINESS OVERVIEW 135
FIGURE 38 SMITH+NEPHEW: COMPANY SNAPSHOT (2021) 136
TABLE 120 SMITH+NEPHEW: PRODUCT OFFERINGS 136
TABLE 121 SMITH+NEPHEW: DEALS 137
11.1.2 MEDIPOST CO., LTD. 138
TABLE 122 MEDIPOST CO., LTD: BUSINESS OVERVIEW 138
FIGURE 39 MEDIPOST CO., LTD: COMPANY SNAPSHOT (2019) 138
TABLE 123 MEDIPOST CO., LTD: PRODUCT OFFERINGS 139
TABLE 124 MEDIPOST CO., LTD: PRODUCT APPROVALS 139
TABLE 125 MEDIPOST CO., LTD: DEALS 139
TABLE 126 MEDIPOST CO., LTD: OTHERS 139
TABLE 127 MEDIPOST CO., LTD: REGULATORY APPROVALS AND PATENTS 140
11.1.3 JCR PHARMACEUTICALS CO., LTD. 141
TABLE 128 JCR PHARMACEUTICALS CO., LTD: BUSINESS OVERVIEW 141
FIGURE 40 JCR PHARMACEUTICALS CO., LTD: COMPANY SNAPSHOT (2021) 141
TABLE 129 JCR PHARMACEUTICALS CO., LTD: PRODUCT OFFERINGS 142
11.1.4 TAKEDA PHARMACEUTICAL COMPANY LIMITED 143
TABLE 130 TAKEDA PHARMACEUTICAL COMPANY LIMITED: BUSINESS OVERVIEW 143
FIGURE 41 TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY SNAPSHOT (2021) 143
TABLE 131 TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCT OFFERINGS 144
TABLE 132 TAKEDA PHARMACEUTICAL COMPANY LIMITED: EXPANSIONS 144
TABLE 133 TAKEDA PHARMACEUTICAL COMPANY LIMITED: REGULATORY APPROVALS 144
11.1.5 ANTEROGEN. CO., LTD. 145
TABLE 134 ANTEROGEN CO., LTD: BUSINESS OVERVIEW 145
TABLE 135 ANTEROGEN CO., LTD: PRODUCT OFFERINGS 145
11.1.6 CORESTEM 146
TABLE 136 CORESTEM: BUSINESS OVERVIEW 146
TABLE 137 CORESTEM: PRODUCT OFFERINGS 146
TABLE 138 CORESTEM: REGULATORY APPROVALS 146
11.1.7 PHARMICELL CO., LTD. 147
TABLE 139 PHARMICELL CO., LTD.: BUSINESS OVERVIEW 147
TABLE 140 PHARMICELL CO., LTD.: PRODUCT OFFERINGS 147
TABLE 141 PHARMICELL CO., LTD.: DEALS 147
11.1.8 NUVASIVE, INC. 148
TABLE 142 NUVASIVE, INC: BUSINESS OVERVIEW 148
FIGURE 42 NUVASIVE, INC: COMPANY SNAPSHOT (2021) 149
TABLE 143 NUVASIVE, INC.: PRODUCT OFFERINGS 149
11.1.9 RTI SURGICAL 150
TABLE 144 RTI SURGICAL: BUSINESS OVERVIEW 150
TABLE 145 RTI SURGICAL: PRODUCT OFFERINGS 150
11.1.10 ALLOSOURCE 151
TABLE 146 ALLOSOURCE: BUSINESS OVERVIEW 151
TABLE 147 ALLOSOURCE: PRODUCT OFFERINGS 151
11.1.11 HOLOSTEM TERAPIE AVANZATE SRL 152
TABLE 148 HOLOSTEM TERAPIE AVANZATE SRL: BUSINESS OVERVIEW 152
TABLE 149 HOLOSTEM TERAPIE AVANZATE SRL: PRODUCT OFFERINGS 152
11.1.12 ORTHOFIX 153
TABLE 150 ORTHOFIX: BUSINESS OVERVIEW 153
FIGURE 43 ORTHOFIX: COMPANY SNAPSHOT (2021) 154
TABLE 151 ORTHOFIX: PRODUCT OFFERINGS 154
11.1.13 STEMPEUTICS RESEARCH 155
TABLE 152 STEMPEUTICS RESEARCH: BUSINESS OVERVIEW 155
TABLE 153 STEMPEUTICS RESEARCH: PRODUCT OFFERINGS 155
11.1.14 REGROW BIOSCIENCES PVT LTD. 156
TABLE 154 REGROW BIOSCIENCES PVT LTD: BUSINESS OVERVIEW 156
TABLE 155 REGROW BIOSCIENCES PVT LTD: PRODUCT OFFERINGS 156
11.2 OTHER PLAYERS (PRODUCTS IN PIPELINE) 157
11.2.1 ATHERSYS, INC. 157
11.2.2 MESOBLAST LTD 157
11.2.3 BIORESTORATIVE THERAPIES, INC. 158
11.2.4 PLURISTEM INC. 158
11.2.5 BRAINSTORM CELL LIMITED. 158
11.2.6 GAMIDA CELL 159
11.2.7 VIACYTE, INC. 159
11.2.8 KANGSTEM BIOTECH 159
11.2.9 HOPE BIOSCIENCES 160
11.2.10 CELLULAR BIOMEDICINE GROUP (CBMG) 160
11.2.11 PERSONALIZED STEM CELLS 160
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
12 APPENDIX 161
12.1 DISCUSSION GUIDE 161
12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 163
12.3 CUSTOMIZATION OPTIONS 165
12.4 RELATED REPORTS 165
12.5 AUTHOR DETAILS 166



★調査レポート[幹細胞療法のグローバル市場予測（～2027）：同種幹細胞療法、自家幹細胞療法] ( Stem Cell Therapy Market by Type (Allogeneic, Autologous), Cell Source (Adipose Tissue-derived MSC, Bone Marrow, Placenta/Umbilical Cord), Therapeutic Application (Musculoskeletal, Wounds, Surgeries, Cardiovascular, Neurological) - Global Forecast to 2027 / BT5049-22) 販売に関する免責事項
[幹細胞療法のグローバル市場予測（～2027）：同種幹細胞療法、自家幹細胞療法] ( Stem Cell Therapy Market by Type (Allogeneic, Autologous), Cell Source (Adipose Tissue-derived MSC, Bone Marrow, Placenta/Umbilical Cord), Therapeutic Application (Musculoskeletal, Wounds, Surgeries, Cardiovascular, Neurological) - Global Forecast to 2027 / BT5049-22) についてEメールでお問い合わせ
◆関連調査資料◆
  • 幹細胞アッセイのグローバル市場予測（～2027）：生存率、増殖、分化、アポトーシス
    BT4628-22 / MarketsandMarkets / 2022年6月21日 / マーケッツアンドマーケッツ社は、世界の幹細胞アッセイ市場規模が、2022年19億ドルから2027年45億ドルまで年平均17.7％成長すると予測しています。本調査資料では、幹細胞アッセイの世界市場について総合的に調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、プレミアムインサイト、市場概要、種類別（生存率/細胞毒性、分離＆精製、細胞識別、増殖、分化）分析、細胞種類別（成体幹細胞、ヒト胚性幹細胞）分析、製品・サービス別（機器、キット、サービス）分析、用途別（再生医療＆治療法開発、創薬＆開発、臨床研究）分析、地域別分析、競争状況、企業情報などの内容をまとめております。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・プレミアムインサイト ・市場概要 ・世界の幹細胞アッセイ市場規模：種類別（生存率/細胞毒性、分離＆精製、細胞識別、増殖、分化） ・世界の幹細胞アッセイ市場規模：細胞種類別（成体幹細胞、ヒト胚性幹細胞） ・世界の幹細胞アッセイ市場規模：製品・サービス別（機器、キット、サービス） ・世界の幹細胞アッセイ市場規模：用途別（再生医療＆治療法開発、創薬＆開発、臨床研究）...“The stem cell assays market is projected to reach USD 4.5 Billion by 2027 from USD 1.9 Billion in 2022, at a CAGR of 17.7% during the forecast period.” The growth of the market is projected to be driven by collaborations and agreements among market players for stem cell assay products & services, launch of new stem cell analysis systems such as flow cytometers and increase in R&D expenditure by biopharmaceutical and biotechnology companies. “The viability/cytotoxicity assays accounted for the largest share of the type segment in the stem cell assays market in 2021.” Cell viability assays help to determine...
  • フローサイトメトリーのグローバル市場予測（～2027）：細胞ベース、ビーズベース
    BT6015-22 / MarketsandMarkets / 2022年8月29日 / MarketsandMarkets社の最新調査レポートによると、世界のフローサイトメトリー市場規模は、2022年47億ドルから2027年69億ドルまで年平均8.1％成長すると推定されます。当書は、フローサイトメトリーの世界市場を調査対象とし、イントロダクション、調査手法、エグゼクティブサマリー、プレミアムインサイト、市場概要、技術別（細胞ベース、ビーズベース）分析、製品＆サービス別（試薬＆消耗品、機器、サービス、ソフトウェア、付属品）分析、用途別（研究用、臨床用、免疫不全疾患用、産業用）分析、エンドユーザー別（学術＆研究機関、病院＆臨床検査室、医薬品＆バイオ医薬品会社）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、競争状況、企業情報などについて総合的にまとめています。なお、当書に掲載されている企業情報には、Becton、Dickinson and Company (US)、Danaher Corporation (US)、Thermo Fisher Scientific, Inc. (US)、Luminex...“The global flow cytometry market is projected to reach USD 6.9 billion by 2027 from USD 4.7 billion in 2022, at a CAGR of 8.1% during the forecast period.” Rising prevalence of HIV/AIDS, cancer & autoimmune diseases across the globe is increasing adoption of flow cytometry for diagnosis hence projecting the market growth. Additionally, launch of technologically advent product is furthermore likely to propel the market growth during the forecast period of 2022-2027. “Instruments segment held a substantial share in the global flow cytometry market in 2021.” Based on product & services, the market is segmented into reagents & consumables,...
  • エピジェネティクスのグローバル市場予測（～2027）：キット＆試薬、酵素、機器＆付属品、ソフトウェア、サービス
    BT2775-22 / MarketsandMarkets / 2022年7月15日 / MarketsandMarkets社の最新調査レポートによると、世界のエピジェネティクス市場規模は、2022年17億ドルから2027年39億ドルまで年平均18.1％拡大すると見込まれています。当書ではエピジェネティクスの世界市場を総合的に調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、プレミアムインサイト、市場概要、製品・サービス別（キット＆試薬、酵素、機器＆付属品、ソフトウェア、サービス）分析、方法別（DNAメチル化、ヒストン修飾、その他）分析、技術別（NGS、PCR＆qPCR、質量分析、超音波処理、その他）分析、用途別（腫瘍、代謝性疾患、免疫、発生生物学、心血管疾患）分析、地域別分析、競争状況、企業情報など、以下の項目を掲載しています。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・プレミアムインサイト ・市場概要 ・世界のエピジェネティクス市場規模：製品・サービス別（キット＆試薬、酵素、機器＆付属品、ソフトウェア、サービス） ・世界のエピジェネティクス市場規模：方法別（DNAメチル化、ヒストン修飾、その他） ・世界のエピジェネティクス市場規模：技術別（NGS、PCR＆qPCR、質量分析、超音波処理、その他） ・世界のエピジェネティクス市場規模：用途別（腫瘍、代謝性疾患、免疫、発生生物学、心血管疾患）...“The global epigenetics market is projected to reach USD 3.9 Billion by 2027 from USD 1.7 Billion in 2022, at a CAGR of 18.1% during the forecast period.” Expanding non-oncology applications of epigenetics research is expected to open up new avenues of market expansion. Recent studies on epigenetics have been targeted toward periodontology, focusing on DNA methylation analysis. Increasing advancements in sequencing technology have opened new avenues for epigenetic studies enabling the assessment of specific genes and genome-wide analyses. With technological advancements, epigenetics research is anticipated to provide crucial information for developing dental medicine and expand the scope of ongoing...
  • 3Dバイオプリンティングのグローバル市場予測（～2027）：3Dバイオプリンター、バイオインク
    BT4971-22 / MarketsandMarkets / 2022年7月12日 / MarketsandMarkets社の最新調査レポートによると、世界の3Dバイオプリンティング市場規模は、2022年13億ドルから2027年33億ドルまで年平均20.8％拡大すると見込まれています。当書では3Dバイオプリンティングの世界市場を総合的に調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、プレミアムインサイト、市場概要、コンポーネント別（3Dバイオプリンター、バイオインク）分析、材料別（ヒドロゲル、細胞外マトリックス、その他）分析、用途別（研究、臨床）分析、エンドユーザー別（研究・学術機関、バイオ医薬品会社、病院）分析、地域別分析、競争状況、企業情報など、以下の項目を掲載しています。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・プレミアムインサイト ・市場概要 ・世界の3Dバイオプリンティング市場規模：コンポーネント別（3Dバイオプリンター、バイオインク） ・世界の3Dバイオプリンティング市場規模：材料別（ヒドロゲル、細胞外マトリックス、その他） ・世界の3Dバイオプリンティング市場規模：用途別（研究、臨床） ・世界の3Dバイオプリンティング市場規模：エンドユーザー別（研究・学術機関、バイオ医薬品会社、病院）...“The global 3D Bioprinting market is valued at an estimated USD 1.3 billion in 2022 and is projected to reach USD 3.3 billion by 2027, at a CAGR of 20.8% during the forecast period.” Factors such as technological advancements in 3D bioprinters and biomaterials, increasing use of 3D bioprinting in the pharmaceutical and cosmetology industries, and rising public and private funding to support bioprinting research activities drive the market growth. However,factors likedearth of skilled professionals and high development and production costs are restraining the growth of this market. “The 3D Bioprinterssegmentaccounted for the highest growth rate in the 3D Bioprintingmarket,...
  • タンジェンシャルフローろ過（TFF）の世界市場予測（～2027）：製品別、材料別、技術別、用途別、エンドユーザー別、地域別
    BT4615-22 / MarketsandMarkets / 2022年4月25日 / マーケッツアンドマーケッツ社は、世界のタンジェンシャルフローろ過（TFF）市場規模が2022年15億ドルから2027年28億ドルまで、年平均13.2％成長すると予想しています。本市場調査資料では、タンジェンシャルフローろ過（TFF）の世界市場を広く調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、プレミアムインサイト、市場概要、製品別（使い捨て式システム、再利用可能式システム、膜フィルター、ろ過付属品）分析、膜材料別（PES、ポリフッ化ビニリデン（PVDF）、ナイロン、ポリテトラフルオロエチレン（PTFE）、混合セルロースエステル・セルロースアセテート（MCE・CA））分析、技術別（精密ろ過、限外ろ過、ナノフィルトレーション、その他）分析、用途別（最終製品処理、原材料ろ過、セル分離、浄水、空気清浄）分析、地域別分析、競争状況、企業情報などの項目を掲載しています。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・プレミアムインサイト ・市場概要 ・世界のタンジェンシャルフローろ過（TFF）市場規模：製品別（使い捨て式システム、再利用可能式システム、膜フィルター、ろ過付属品） ・世界のタンジェンシャルフローろ過（TFF）市場規模：膜材料別（PES、ポリフッ化ビニリデン（PVDF）、ナイロン、ポリテトラフルオロエチレン（PTFE）、混合セルロースエステル・セルロースアセテート（MCE・CA）） ・世界のタンジェンシャルフローろ過（TFF）市場規模：技術別（精密ろ過、限外ろ過、ナノフィルトレーション、その他） ・世界のタンジェンシャルフローろ過（TFF）市場規模：用途別（最終製品処理、原材料ろ過、セル分離、浄水、空気清浄）...“The global tangential flow filtration market is projected to USD 2.8 billion by 2027 from USD 1.5 billion in 2022, at a CAGR of 13.2% during the forecast period.” The rising advantages of tangential flow filtration over normal flow filtration, increasing adoption of single-use technologies, and growing R&D spending in pharma-biotech companies. On the contrary, the high capital investments for setting up new production facilities are expected to restrain the market growth. “In 2021 the single-use systems segment accounted for the largest share of the tangential flow market.” The tangential flow filtration market is segmented into single-use systems, reusable systems,...
  • フィルフィニッシュ製造のグローバル市場予測（～2027）：消耗品、機器
    PH7648-22 / MarketsandMarkets / 2022年9月17日 / MarketsandMarkets社の最新調査レポートによると、世界のフィルフィニッシュ製造市場規模は、2022年92億ドルから2027年152億ドルまで年平均10.7％成長すると推定されます。当書は、フィルフィニッシュ製造の世界市場を調査対象とし、イントロダクション、調査手法、エグゼクティブサマリー、プレミアムインサイト、市場概要、製品別（消耗品、機器）分析、エンドユーザー別（CMO、医薬品＆バイオ医薬品会社、その他）分析、地域別（ヨーロッパ、北米、アジア太平洋、中南米、中東・アフリカ）分析、競争状況、企業情報などについて総合的にまとめています。なお、当書に掲載されている企業情報には、Becton、Dickson and Company (US)、Syntegon Technology GmbH (Germany)、I.M.A. (Industria Macchine Automatiche)...“The global fill-finish manufacturing market size is projected to grow from USD 15.2 billion by 2027 from USD 9.2 billion in 2022 at a CAGR of 10.7% from 2022 to 2027.” Factors such as the rising adoption of prefilled syringes for parenteral dosage forms and increasing technological advancements are driving the market. The high costs associated with restricted access barrier systems (RABS) is a factor expected to limit the growth of this market. “The prefilled syringes segment is expected to grow at the highest CAGR during the forecast period in the fill-finish manufacturing market.” The consumables segment is divided into...
  • 気管支鏡検査のグローバル市場予測（～2027）：気管支鏡、画像システム、付属品、その他
    MD7495-22 / MarketsandMarkets / 2022年9月20日 / MarketsandMarkets社の最新調査レポートによると、世界の気管支鏡検査市場規模は、2022年25億ドルから2027年37億ドルまで年平均7.9％成長すると推定されます。当書は、気管支鏡検査の世界市場を調査対象とし、イントロダクション、調査手法、エグゼクティブサマリー、プレミアムインサイト、市場概要、製品別（気管支鏡、画像システム、付属品、その他）分析、用途別（気管支治療、気管支診断）分析、有用性別（再利用可能、使い捨て）分析、エンドユーザー別（病院、ACS/クリニック）分析、地域別（北米、ヨーロッパ、アジア太平洋、その他地域）分析、競争状況、企業情報、隣接・関連市場などについて総合的にまとめています。なお、当書に掲載されている企業情報には、Olympus Corporation (Japan)、KARL STORZ (Germany)、Ambu A/S (Denmark)、Boston Scientific Corporation (US)、FUJIFILM...“The global bronchoscopy market is projected to reach USD 3.7 Billion by 2027 from USD 2.5 Billion in 2022, at a CAGR of 7.9% during the forecasted period (2022 to 2027).” Market growth is largely driven by the rising prevalence of respiratory diseases, the growing demand for minimally invasive surgeries, growing hospital investments in bronchoscopy facilities, and technological advancements in bronchoscopes. On the other hand, the dearth of trained physicians and pulmonologists is a major challenge to the growth of this market. “The Bronchoscopes are accounted to hold the largest share of the bronchoscopy market, by product in 2021.” Based...
  • 動物用医療機器＆備品のグローバル市場予測（～2027）：消耗品、患者モニター、麻酔、輸液ポンプ
    MD3898-22 / MarketsandMarkets / 2022年6月24日 / マーケッツアンドマーケッツ社は、世界の動物用医療機器＆備品市場規模が、2022年20億ドルから2027年29億ドルまで年平均8.1％成長すると予測しています。本調査資料では、動物用医療機器＆備品の世界市場について総合的に調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、プレミアムインサイト、市場概要、種類別（消耗品、麻酔装置、流体管理装置、体温管理装置、患者モニター）分析、用途別（手術用、診断・監視・治療用）分析、動物別（小型伴侶動物、大型動物、その他）分析、エンドユーザー別（動物病院、動物クリニック、動物医療研究機関）分析、地域別分析、競争状況、企業情報などの内容をまとめております。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・プレミアムインサイト ・市場概要 ・世界の動物用医療機器＆備品市場規模：種類別（消耗品、麻酔装置、流体管理装置、体温管理装置、患者モニター） ・世界の動物用医療機器＆備品市場規模：用途別（手術用、診断・監視・治療用） ・世界の動物用医療機器＆備品市場規模：動物別（小型伴侶動物、大型動物、その他） ・世界の動物用医療機器＆備品市場規模：エンドユーザー別（動物病院、動物クリニック、動物医療研究機関）...Veterinary equipment and supplies include all kinds of medical equipment, which are intended to help diagnose, monitor, or treat various health conditions associated with animals, such as anesthetic medication, respiratory support, temperature management, and fluid management. It also includes disposable devices or the medical apparatus, which has been designed for temporary or one-time use, mainly for infection control. “The global veterinary equipment and supplies market is projected to reach USD 2.9 Billion by 2027 from USD 2.0 Billion in 2022, at a CAGR of 8.1% during the forecast period.” Emerging markets, such as rIndia and China, and growing companion animal...
  • 医療用語ソフトウェアのグローバル市場予測（～2027）：データ集約、償還、公衆衛生監視、データ統合、臨床試験
    HIT6988-22 / MarketsandMarkets / 2022年7月21日 / MarketsandMarkets社の最新調査レポートによると、世界の医療用語ソフトウェア市場規模は、2022年10億ドルから2027年25億ドルまで年平均19.3％拡大すると見込まれています。当書では医療用語ソフトウェアの世界市場を総合的に調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、プレミアムインサイト、市場概要、産業動向、用途別（データ集約、償還、公衆衛生監視、データ統合、臨床試験）分析、製品・サービス別（サービス、プラットフォーム）分析、エンドユーザー別（医療提供者、医療費支払い者、ITベンダー）分析、地域別分析、競争状況、企業情報など、以下の項目を掲載しています。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・プレミアムインサイト ・市場概要 ・産業動向 ・世界の医療用語ソフトウェア市場規模：用途別（データ集約、償還、公衆衛生監視、データ統合、臨床試験） ・世界の医療用語ソフトウェア市場規模：製品・サービス別（サービス、プラットフォーム） ・世界の医療用語ソフトウェア市場規模：エンドユーザー別（医療提供者、医療費支払い者、ITベンダー）...“The global medical terminology software market is projected to reach USD 2.5 billion by 2027 from an estimated USD 1.0 billion in 2022, at a CAGR of 19.3% during the forecast period.” Growth in this market is driven by the opportunities provided by the market such as emerging markets for medical terminology software market, and increasing need to maintain data integrity. However, the reluctance to use terminology solutions over conventional practices is a challenge that is expected to limit the growth of the market to a certain extent during the forecast period. “The data aggregation segment is projected to be...

    • ◆H&Iグローバルリサーチ株式会社のお客様（例）◆